Sou Hu Cai Jing·2026-02-03 01:37Group 1 - The core message of the news is the significant investment plans by AstraZeneca in China, particularly in Qingdao, as part of the UK Prime Minister's visit to China, signaling a potential revival of UK-China relations and economic cooperation [1][3][10] - AstraZeneca plans to invest over 100 billion yuan (approximately 15 billion USD) in China by 2030, focusing on expanding its pharmaceutical production and R&D capabilities [3][10] - The investment will include upgrades to existing production bases in cities like Wuxi, Taizhou, Qingdao, and Beijing, as well as the establishment of new production facilities [3][10][12] Group 2 - AstraZeneca's total investment in Qingdao has increased from 450 million USD to 886 million USD over three years, indicating a strong commitment to expanding its operations in the region [6][8] - The company aims to create over 20,000 jobs in China, contributing to the local healthcare ecosystem and enhancing Qingdao's position in AstraZeneca's global business strategy [9][12] - The investment is expected to accelerate project construction in Qingdao, with plans for production facilities to be operational by 2028 and 2030 [9][10] Group 3 - The visit of UK Prime Minister Starmer, accompanied by a large business delegation, highlights the UK's intention to repair and enhance trade relations with China, particularly in sectors like finance, automotive, and pharmaceuticals [3][14] - Other companies in the delegation, such as HSBC and PwC, have established connections with Qingdao, indicating a broader interest in fostering economic ties between the UK and Qingdao [14][15] - Qingdao's government has actively sought to attract UK investments, emphasizing the importance of creating a favorable business environment to facilitate these partnerships [21][22]